The global status of HIV drug resistance: Clinical and public-health approaches for detection, treatment and prevention

Infectious Disorders - Drug Targets

Volumn 11, Issue 2, 2011, Pages 124-133

  Hong, Steven Y ^a   Nachega, Jean B ^b,c   Kelley, Karen ^d   Bertagnolio, Silvia ^d   Marconi, Vincent C ^e   Jordan, Michael R ^a,d  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence; Antiretroviral therapy; Drug resistance; Epidemiology; HIV

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL RESISTANCE; ARTICLE; GENOTYPE; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MORBIDITY; MORTALITY; NONHUMAN; PATIENT COMPLIANCE; PHENOTYPE; POPULATION RESEARCH; STANDARDIZATION; WORLD HEALTH ORGANIZATION;

EID: 79954466225     PISSN: 18715265     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152611795589744     Document Type: Article

References (101)

1. WHO, UNAIDS, UNICEF. Towards universal access: scaling up priority HIV /AIDS interventions in the health sector. Progress Report 2010. http://www.who.int/HIV/pub/2010progressreport/report/en/index.html (Accessed October 29, 2010).
2. WHO, UNAIDS, UNICEF. Towards universal access: scaling up priority HIV /AIDS interventions in the health sector. Progress Report 2009. http://www.who.int/HIV/pub/2009progressreport/en/ (Accessed October 29, 2010).
3. Gilks, C. F.; Crowley, S.; Ekpini, R.; Gove, S.; Perriens, J.; Souteyrand, Y.; Sutherland, D.; Vitoria, M.; Guerma, T.; De Cock, K. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet, 2006, 368, 505-510.
4. Boyd, M. A.; Cooper, D. A. Second-Line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research. AIDS, 2007, 21(Suppl. 4), S55-63.
5. Bartlett, J. A.; Shao, J. F. Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. Lancet Infect. Dis., 2009, 9, 637-649.
6. Ford, N.; Wilson, D.; Costa Chaves, G.; Lotrowska, M.; Kijtiwatchakul, K. Sustaining access to antiretroviral therapy in the less-developed world: lessons from brazil and thailand. AIDS, 2007, 21(Suppl 4), S21-29.
7. Lucas, G. M.; Chaisson, R. E.; Moore, R. D. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann. Intern. Med., 1999, 131, 81-87.
8. Paterson, D. L.; Swindells, S.; Mohr, J.; Brester, M.; Vergis, E. N.; Squier, C.; Wagener, M. M.; Singh, N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med., 2000, 133, 21-30.
9. Arnsten, J. H.; Demas, P. A.; Farzadegan, H.; Grant, R. W.; Gourevitch, M. N.; Chang, C. J.; Buono, D.; Eckholdt, H.; Howard, A. A.; Schoenbaum, E. E. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin. Infect. Dis., 2001, 33, 1417-1423.
10. Nachega, J. B.; Hislop, M.; Dowdy, D. W.; Chaisson, R. E.; Regensberg, L.; maartens, g. adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann. Intern. Med., 2007, 146, 564-573.
11. Shuter, J.; Sarlo, J. A.; Kanmaz, T. J.; Rode, R. A.; Zingman, B. S. HIV-Infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J. Acquir. Immune Defic. Syndr., 2007, 45, 4-8.
12. Martin, M.; Del Cacho, E.; Codina, C.; Tuset, M.; De Lazzari, E.; Mallolas, J.; Miro, J. M.; Gatell, J. M.; Ribas, J. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 rna viral load: a prospective cohort study. AIDS Res. Hum. Retroviruses, 2008, 24, 1263-1268.
13. Bangsberg, D. R.; Acosta, E. P.; Gupta, R.; Guzman, D.; Riley, E. D.; Harrigan, P. R.; Parkin, N.; Deeks, S. G. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS, 2006, 20, 223-231.
14. Harrigan, P. R.; Hogg, R. S.; Dong, W. W.; Yip, B.; Wynhoven, B.; Woodward, J.; Brumme, C. J.; Brumme, Z. L.; Mo, T.; Alexander, C. S.; Montaner, J. S. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J. Infect. Dis., 2005, 191, 339-347.
15. Bangsberg, D. R.; Perry, S.; Charlebois, E. D.; Clark, R. A.; Roberston, M.; Zolopa, A. R.; Moss, A. Non-adherence to highly active antiretroviral therapy predicts progression to aids. AIDS, 2001, 15, 1181-1183.
16. Hogg, R. S.; Heath, K.; Bangsberg, D.; Yip, B.; Press, N.; O'Shaughnessy, M. V.; Montaner, J. S. Intermittent use of triplecombination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS, 2002, 16, 1051-1058.
17. Nachega, J. B.; Hislop, M.; Dowdy, D. W.; Lo, M.; Omer, S. B.; Regensberg, L.; Chaisson, R. E.; Maartens, G. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected south african adults. J. Acquir. Immune Defic. Syndr., 2006, 43, 78-84.
18. Wood, E.; Hogg, R. S.; Yip, B.; Moore, D.; Harrigan, P. R.; Montaner, J. S. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > Or = 200 cells/microl. AIDS, 2006, 20, 1117-1123.
19. Oyugi, J. H.; Byakika-Tusiime, J.; Charlebois, E. D.; Kityo, C.; Mugerwa, R.; Mugyenyi, P.; Bangsberg, D. R. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-Limited Setting. J. Acquir. Immune Defic. Syndr., 2004, 36, 1100-1102.
20. Orrell, C.; Bangsberg, D. R.; Badri, M.; Wood, R. Adherence is not a barrier to successful antiretroviral therapy in south africa. AIDS, 2003, 17, 1369-1375.
21. Nachega, J. B.; Stein, D. M.; Lehman, D. A.; Hlatshwayo, D.; Mothopeng, R.; Chaisson, R. E.; Karstaedt, A. S. Adherence to antiretroviral therapy in HIV-infected adults in soweto, south africa. AIDS Res. Hum. Retroviruses, 2004, 20, 1053-1056.
22. Mills, E. J.; Nachega, J. B.; Buchan, I.; Orbinski, J.; Attaran, A.; Singh, S.; Rachlis, B.; Wu, P.; Cooper, C.; Thabane, L.; Wilson, K.; Guyatt, G. H.; Bangsberg, D. R. Adherence to antiretroviral therapy in sub-saharan Africa and North America: A meta-analysis. JAMA, 2006, 296, 679-690.
23. Richman, D. D.; Morton, S. C.; Wrin, T.; Hellmann, N.; Berry, S.; Shapiro, M. F.; Bozzette, S. A. The prevalence of antiretroviral drug resistance in the United States. AIDS, 2004, 18, 1393-1401.
24. Bennett, D. E.; Bertagnolio, S.; Sutherland, D.; Gilks, C. F. The world health organization's global strategy for prevention and assessment of HIV drug resistance. Antivir. Ther., 2008, 13(Suppl. 2), 1-13.
25. Parienti, J. J.; Massari, V.; Descamps, D.; Vabret, A.; Bouvet, E.; Larouze, B.; Verdon, R. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine-or efavirenz-based antiretroviral therapy. Clin. Infect. Dis., 2004, 38, 1311-1316.
26. Oyugi, J. H.; Byakika-Tusiime, J.; Ragland, K.; Laeyendecker, O.; Mugerwa, R.; Kityo, C.; Mugyenyi, P.; Quinn, T. C.; Bangsberg, D. R. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in kampala, uganda. AIDS, 2007, 21, 965-971.
27. Marcellin F.; Boyer S.; Protopopescu C.; Dia A.; Ongolo-Zogo P.; Koulla-Shiro S.; Abega S.-C.; Abe C.; Moatti J.-P.; Spire B.; Carrieri M.P.; EVAL Study Group. Determinants of unplanned antiretroviral treatment interruptions among people living with HIV in Yaoundé, Cameroon. (EVAL survey, ANRS 12-116). Trop. Med. Intl. Health, 2009, 13, 1470-1478.
28. Eholie, S. P.; Tanon, A.; Polneau, S.; Ouiminga, M.; Djadji, A.; Kangah-Koffi, C.; Diakite, N.; Anglaret, X.; Kakou, A.; Bissagnene, E. Field adherence to highly active antiretroviral therapy in HIV-infected adults in abidjan, cote d'Ivoire. J. Acquir. Immune. Defic. Syndr., 2007, 45, 355-358.
29. Tuller, D. M.; Bangsberg, D. R.; Senkungu, J.; Ware, N. C.; Emenyonu, N.; Weiser, S. D. Transportation costs impede sustained adherence and access to haart in a clinic population in southwestern uganda: a qualitative study. AIDS. Behav., 2010, 14, 778-784.
30. Little, S. J.; Holte, S.; Routy, J. P.; Daar, E. S.; Markowitz, M.; Collier, A. C.; Koup, R. A.; Mellors, J. W.; Connick, E.; Conway, B.; Kilby, M.; Wang, L.; Whitcomb, J. M.; Hellmann, N. S.; Richman, D. D. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med., 2002, 347, 385-394.
31. Grant, R. M.; Hecht, F. M.; Warmerdam, M.; Liu, L.; Liegler, T.; Petropoulos, C. J.; Hellmann, N. S.; Chesney, M.; Busch, M. P.; Kahn, J. O. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA, 2002, 288, 181-188.
32. Violin, M.; Cozzi-Lepri, A.; Velleca, R.; Vincenti, A.; D'Elia, S.; Chiodo, F.; Ghinelli, F.; Bertoli, A.; d'Arminio Monforte, A.; Perno, C. F.; Moroni, M.; Balotta, C. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analogcontaining highly active antiretroviral therapy. AIDS, 2004, 18, 227-235.
33. Wensing A.M.; van de Vijver D.A.; Angarano G.; Asjö B.; Balotta C.; Boeri E.; Camacho R.; Chaix M.L.; Costagliola D.; De Luca.; Derdelinckx I.; Grossman Z.; Hamouda O.; Hatzakis A.; Hemmer R.; Hoepelman A.; Horban A.; Korn K.; Kücherer C.; Leitner T.; Loveday C.; MacRae E.; Maljkovic I.; de Mendoza C.; Meyer L.; Nielsen C.; Op de Coul EL.; Ormaasen V.; Paraskevis D.; Perrin L.; Puchhammer-Stöckl E.; Ruiz L.; Salminen M.; Schmit J.C.; Schneider F.; Schuurman R.; Soriano V.; Stanczak G.; Stanojevic M.; Vandamme A.M.; Van Laethem K.; Violin M.; Wilbe K.; Yerly S.; Zazzi M.; Boucher CA.; SPREAD programme. prevalence of drug-resistant HIV-1 variants in untreated individuals in europe: implications for clinical management. J. Infect. Dis., 2005, 192, 958-966.
34. Vercauteren J.; Wensing A.M.; van de Vijver D.A.; Albert J.; Balotta C.; Hamouda O.; Kücherer C.; Struck D.; Schmit J.C.; Asjö B.; Bruckova M.; Camacho R.J.; Clotet B.; Coughlan S.; Grossman Z.; Horban A.; Korn K.; Kostrikis L.; Nielsen C.; Paraskevis D.; Poljak M.; Puchhammer-Stöckl E.; Riva C.; Ruiz L.; Salminen M.; Schuurman R.; Sonnerborg A.; Stanekova D.; Stanojevic M.; Vandamme A.M.; Boucher C.A. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J. Infect. Dis., 2009, 200, 1503-1508.
35. Little S.J.; May S.; Hecht F.; Markowitz M.; Daar E.S.; Kaldor J.; Grant R.M.; Bates M.; Woelk C.; Kosakovsky Pond S.L.; Liu L.; Degruttola V.; Frost S.D.W.; Richman D.D. Increase in transmitted NNRTI drug resistance among recently HIV infected patients from North America and Australia. Antivir. Ther., 2006, 11(Suppl 1), S110.
36. Ross L.L.; Florance A.; Wine B.; Craig C.; Vavro C.; McClernon D.; Tisdale M.; Baul R.; Lancaster T.; Shaefer M.; Lanier E.R.; Prevalence of HIV-1 drug resistance-associated mutations in a large cohort of antiretroviral therapy (ART) naïve HIV-infected individuals in the United States from 2000-2004. Antivir. Ther., 2006, 11 Suppl 1, S120.
37. Bennett D.; Zaidi I.; Heneine W.; Woods T.; García-Lerma G.; Kaplan J.; Weinstock H. Prevalence of mutations associated with antiretroviral drug resistance among recently diagnosed persons with HIV, 1998-2000. 9th Conference on Retroviruses & Opportunistic Infections, 2002, Seattle, Wash., USA, Abstract 372-M. 24-28 February.
38. Wheeler W.; Mahle K.; Bodnar U.; Kline R.; Hall I.; McKenna M.; and the US Variant, Atypical and Resistant HIV Surveillance (VARHS) Group. Antiretroviral Drug-resistance Mutations and Subtypes in Drug-naïve Persons Newly Diagnosed with HIV-1 Infection, US, March 2003 to October 2006. 14th Conference on Retroviruses & Opportunistic Infections, 2007, Los Angeles, CA, USA, Abstract 648. 25-28 February.
39. Wheeler, W. H.; Ziebell, R. A.; Zabina, H.; Pieniazek, D.; Prejean, J.; Bodnar, U. R.; Mahle, K. C.; Heneine, W.; Johnson, J. A.; Hall, H. I.; Variant, atypical, and resistant HIV Surveillance group prevalence of transmitted Drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS, 2010, 24, 1203-1212.
40. Kim D.; Wheeler W.; Zieball R.; Johnson J.; Prejean J.; Heneine W.; Hall I.; and US Variant, Atypical, and Resistant HIV Surveillance Coordinators. Prevalence of transmitted antiretroviral drug resistance among newly-diagnosed HIV-1-infected persons, US, 2007. 17th Conference on Retroviruses & Opportunistic Infections, 16-19 February, 2010, San Francisco, CA, USA, Abstract 580.
41. Ross L.L.; Wine B.; Horton J.H.; Vavro C.; St Clair M.; Ha B.F.; Pappa K.A.; Schaefer M. Prevalence of HIV-1 drug resistanceassociated mutations in a large cohort of antiretroviral naïve HIV-infected individuals in the USA from 2000-2009. Antivir. Ther., 2010, 15(Suppl. 2), A50.
42. Bowles E.; Wensing A.M.J.; van de Vijver D.A.M.C.; Boulme R.; Schuurman R.; Boucher C.; on behalf of all WATCH inverstigators. WATCH: a worldwide database for collecting and analyzing data on transmission of drug resistant HIV using standardized methods. XVIth International AIDS Conference, 3-8 August 2006, Toronto, Canada, Abstract MOPE0388.
43. Hamers, R. L.; Derdelinckx, I.; van Vugt, M.; Stevens, W.; Rinke de Wit, T. F.; Schuurman, R.; Pharmaccess African studies to evaluate resistance programme The status of HIV-1 resistance to antiretroviral drugs in sub-saharan Africa. Antivir. Ther., 2008, 13, 625-639.
44. De Luca, A.; Prosperi, M.; Bracciale, L. Resistance considerations in sequencing of antiretroviral therapy in low-middle income countries with currently available options. Curr. Opin. HIV. AIDS., 2010, 5, 27-37.
45. Bartolo, I.; Rocha, C.; Bartolomeu, J.; Gama, A.; Fonseca, M.; Mendes, A.; Cristina, F.; Thamm, S.; Epalanga, M.; Silva, P. C.; Taveira, N. Antiretroviral drug resistance surveillance among treatment-naive human immunodeficiency virus type 1-infected individuals in angola: evidence for low level of transmitted drug resistance. Antimicrob. Agents Chemother., 2009, 53, 3156-3158.
46. Tu, Y. Q.; Wang, M. J.; Yao, J.; Zhu, X. M.; Pan, P. L.; Xing, W. G.; Zhang, G. H.; Yang, R. G.; Zheng, Y. T.; Jiang, Y. Human immunodeficiency virus-1 genotypic drug resistance among volunteer blood donors in yunnan, china. Transfusion, 2009, 49, 1865-1873.
47. Yaotse, D. A.; Nicole, V.; Roch, N. F.; Mireille, P. D.; Eric, D.; Martine, P. Genetic Characterization of HIV-1 Strains in togo reveals a high genetic complexity and genotypic drug-resistance mutations in ARV naive Patients. Infect. Genet. Evol., 2009, 9, 646-652.
48. Derache, A.; Maiga, A. I.; Traore, O.; Akonde, A.; Cisse, M.; Jarrousse, B.; Koita, V.; Diarra, B.; Carcelain, G.; Barin, F.; Pizzocolo, C.; Pizarro, L.; Katlama, C.; Calvez, V.; Marcelin, A. G. Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from mali between 2005 and 2006. J. Antimicrob. Chemother., 2008, 62, 456-463.
49. Blower, S.; Bodine, E.; Kahn, J.; McFarland, W. The antiretroviral rollout and drug-resistant hiv in africa: Insights from empirical data and theoretical models. AIDS, 2005, 19, 1-14.
50. Coffin, J. M. HIV Population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science, 1995, 267, 483-489.
51. Durant, J.; Clevenbergh, P.; Halfon, P.; Delgiudice, P.; Porsin, S.; Simonet, P.; Montagne, N.; Boucher, C. A.; Schapiro, J. M.; Dellamonica, P. Drug-resistance Genotyping in HIV-1 Therapy: The viradapt randomised controlled trial. Lancet, 1999, 353, 2195-2199.
52. Baxter, J. D.; Mayers, D. L.; Wentworth, D. N.; Neaton, J. D.; Hoover, M. L.; Winters, M. A.; Mannheimer, S. B.; Thompson, M. A.; Abrams, D. I.; Brizz, B. J.; Ioannidis, J. P.; Merigan, T. C. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 study team for the terry beirn community programs for clinical research on AIDS. AIDS, 2000, 14, F83-93.
53. Tural, C.; Ruiz, L.; Holtzer, C.; Schapiro, J.; Viciana, P.; Gonzalez, J.; Domingo, P.; Boucher, C.; Rey-Joly, C.; Clotet, B.; Havana study group. Clinical utility of HIV-1 genotyping and expert advice: the havana trial. AIDS, 2002, 16, 209-218.
54. Cohen, C. J.; Hunt, S.; Sension, M.; Farthing, C.; Conant, M.; Jacobson, S.; Nadler, J.; Verbiest, W.; Hertogs, K.; Ames, M.; Rinehart, A. R.; Graham, N. M.; VIRA3001 Study team a randomized trial assessing the impact of phenotypic resistance testing on antiretroviral THerapy. AIDS, 2002, 16, 579-588.
55. Cingolani, A.; Antinori, A.; Rizzo, M. G.; Murri, R.; Ammassari, A.; Baldini, F.; Di Giambenedetto, S.; Cauda, R.; De Luca, A. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS, 2002, 16, 369-379.
56. Meynard, J. L.; Vray, M.; Morand-Joubert, L.; Race, E.; Descamps, D.; Peytavin, G.; Matheron, S.; Lamotte, C.; Guiramand, S.; Costagliola, D.; Brun-Vezinet, F.; Clavel, F.; Girard, P. M.; Narval trial group phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: A randomized trial. AIDS, 2002, 16, 727-736.
57. Haubrich, R. H.; Kemper, C. A.; Hellmann, N. S.; Keiser, P. H.; Witt, M. D.; Tilles, J. G.; Forthal, D. N.; Leedom, J.; Leibowitz, M.; McCutchan, J. A.; Richman, D. D.; California collaborative treatment Group A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS, 2005, 19, 295-302.
58. Wegner, S. A., et al. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. Clin. Infect. Dis., 2004, 38, 723-730.
59. The European HIV Drug Resistance Guidelines Panel. The European HIV Drug Resistance Guidelines 2009 Update. http://www.europeanaidsclinicalsociety.org/The (Accessed October 30, 2010).
60. Panel on Antiretroviral Guidelines for Adults and Adolescents. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://www.aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf (Accessed October 30, 2010).
61. Hirsch M.S.; Günthard H.F.; Schapiro J.M.; Brun-Vézinet F.; Clotet B.; Hammer S.M.; Johnson V.A.; Kuritzkes D.R.; Mellors J.W.; Pillay D.; Yeni P.G.; Jacobsen D.M.; Richman D.D.; International AIDS Society-USA. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Top. HIV Med., 2008, 16(3), 266-85.
62. UK Collaborative Group on HIV Drug Resistance: UK CHIC Study Group. Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clin. Infect. Dis., 2010, 50(9), 1275-85.
63. Phillips, A.N.; Leen, C.; Wilson, A.; Anderson, J.; Dunn, D.; Schwenk, A.; Orkin, C.; Hill, T.; Fisher, M.; Walsh, J.; Pillay, D.; Bansi, L.; Gazzard, B.; Easterbrook, P.; Gilson, R.; Johnson, M.; Sabin, C.A. UK Collaborative HIV Cohort (CHIC) Study.l Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: An observational cohort study. Lancet, 2007, 370, 1923-1928.
64. Cozzi-Lepri, A.; Phillips, A. N.; Clotet, B.; Mocroft, A.; Ruiz, L.; Kirk, O.; Lazzarin, A.; Wiercinska-Drapalo, A.; Karlsson, A.; Lundgren, J. D.; EuroSIDA study group detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. AIDS, 2008, 22, 2187-2198.
65. Zaccarelli, M.; Tozzi, V.; Lorenzini, P.; Trotta, M. P.; Forbici, F.; Visco-Comandini, U.; Gori, C.; Narciso, P.; Perno, C. F.; Antinori, A.; Collaborative group for clinical use of HIV genotype resistance test (grt) at national institute for infectious diseases lazzaro spallanzani multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS, 2005, 19, 1081-1089.
66. Di Giambenedetto, S.; Colafigli, M.; Pinnetti, C.; Bacarelli, A.; Cingolani, A.; Tamburrini, E.; Cauda, R.; de Luca, A. Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. AIDS Res. Hum. Retroviruses, 2008, 24, 149-154.
67. Ormaasen, V.; Sandvik, L.; Asjo, B.; Holberg-Petersen, M.; Gaarder, P. I.; Bruun, J. N. An algorithm-based genotypic resistance score is associated with clinical outcome in HIV-1-infected adults on antiretroviral therapy. HIV. Med., 2004, 5, 400-406.
68. Napravnick S.; Keys J.; Stalzer B.; Eron J.J. Extensive HIV-1 antiretroviral drug class resistance is associated with inferior virological and clinical outcomes. Antivir. Ther., 2007, 12(Suppl. 1), S68.
69. Lohse, N.; Jorgensen, L. B.; Kronborg, G.; Moller, A.; Kvinesdal, B.; Sorensen, H. T.; Obel, N.; Gerstoft, J.; Danish HIV cohort study genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug Failure. Antivir. Ther., 2007, 12, 909-917.
70. Lucas, G. M.; Gallant, J. E.; Moore, R. D. Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance Testing. AIDS, 2004, 18, 1539-1548.
71. Lucas, G. M. Antiretroviral adherence, Drug resistance, viral fitness and HIV disease progression: a tangled web is woven. J. Antimicrob. Chemother., 2005, 55, 413-416.
72. Hogg, R. S.; Bangsberg, D. R.; Lima, V. D.; Alexander, C.; Bonner, S.; Yip, B.; Wood, E.; Dong, W. W.; Montaner, J. S.; Harrigan, P. R. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med., 2006, 3, e356.
73. Kozal, M. J.; Hullsiek, K. H.; Macarthur, R. D.; Berg-Wolf, M.; Peng, G.; Xiang, Y.; Baxter, J. D.; Uy, J.; Telzak, E. E.; Novak, R. M.; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) The incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naive participants started on three different antiretroviral therapy strategies. HIV. Clin. Trials, 2007, 8, 357-370.
74. Palella, F. J., Jr; Armon, C.; Buchacz, K.; Cole, S. R.; Chmiel, J. S.; Novak, R. M.; Wood, K.; Moorman, A. C.; Brooks, J. T.; HOPS (HIV Outpatient Study) investigators the association of HIV susceptibility testing with survival among HIV-infected patients re ceiving antiretroviral therapy: a cohort study. Ann. Intern. Med., 2009, 151, 73-84.
75. Assoumou L.; Descamps D.; Yerly S.; Dos Santos G.; Marcelin A.G.; Delaguerre C.; Ruffault A.; Izopet J.; Plantier J.-C.; Pakianather S.; Montes B.; Chaix M.L.; Calvez V.; Costagliola D.; Masquelier B.; the ANRS AC11 Resistance Study Group. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/ml in 2009: a French nationwide study. Antivir. Ther., 2010, 15 Suppl 2, A185.
76. Barth, R. E.; van der Loeff, M. F.; Schuurman, R.; Hoepelman, A. I.; Wensing, A. M. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-saharan africa: a systematic review. Lancet Infect. Dis., 2010, 10, 155-166.
77. Gupta, R. K.; Pillay, D. HIV Resistance and the developing world. Int. J. Antimicrob. Agents, 2007, 29, 510-517.
78. Marconi, V. C.; Sunpath, H.; Lu, Z.; Gordon, M.; Koranteng-Apeagyei, K.; Hampton, J.; Carpenter, S.; Giddy, J.; Ross, D.; Holst, H.; Losina, E.; Walker, B. D.; Kuritzkes, D. R.; South Africa resistance cohort study team prevalence of HIV-1 Drug resistance after failure of a first highly active antiretroviral therapy regimen in kwazulu natal, South Africa. Clin. Infect. Dis., 2008, 46, 1589-1597.
79. Weidle, P. J.; Malamba, S.; Mwebaze, R.; Sozi, C.; Rukundo, G.; Downing, R.; Hanson, D.; Ochola, D.; Mugyenyi, P.; Mermin, J.; Samb, B.; Lackritz, E. Assessment of a pilot antiretroviral drug therapy programme in uganda: patients' response, survival, and drug resistance. Lancet, 2002, 360, 34-40.
80. Adjé, C.; Cheingsong, R.; Roels, T.H.; Maurice, C.; Djomand, G.; Verbiest, W.; Hertogs, K.; Larder, B.; Monga, B.; Peeters, M.; Eholie, S.; Bissagene, E.; Coulibaly, M.; Respess, R.; Wiktor, S.Z.; Chorba, T.; Nkengasong, J.N. UNAIDS HIV Drug Access Initiative, Abidjan, Côte d'Ivoire. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in abidjan, cote d'Ivoire. J. Acquir. Immune Defic. Syndr., 2001, 26, 501-506.
81. Vergne, L.; Malonga-Mouellet, G.; Mistoul, I.; Mavoungou, R.; Mansaray, H.; Peeters, M.; Delaporte, E. Resistance to antiretroviral treatment in gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 Drug resistance monitoring in developing countries. J. Acquir. Immune Defic. Syndr., 2002, 29, 165-168.
82. Tebit, D. M.; Sangare, L.; Makamtse, A.; Yameogo, S.; Somlare, H.; Bado, G.; Kouldiaty, B. G.; Sathiandee, K.; Tiba, F.; Sanou, I.; Ouedraogo-Traore, R.; Zoungrana, L.; Diallo, I.; Drabo, J. Y.; Krausslich, H. G. HIV Drug resistance pattern among HAARTexposed patients with suboptimal virological response in ouagadougou, burkina faso. J. Acquir. Immune Defic. Syndr., 2008, 49, 17-25.
83. Bennett D.E.; Myatt M.; Bertagnolio S.; Sutherland D.; Gilks C.F. Recommendations for surveillance of transmitted HIV Drug resistance in countries scaling up antiretroviral treatment. Antivir. Ther., 2008, 13 Suppl 2, 25-36.
84. Jordan, M. R.; Bennett, D. E.; Bertagnolio, S.; Gilks, C. F.; Sutherland, D. World Health Organization Surveys to Monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther., 2008, 13 Suppl 2, 15-23.
85. Myatt, M.; Bennett, D. E. A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by crosssectional survey for use in low resource settings. Antivir Ther., 2008, 13 Suppl 2, 37-48.
86. Bennett D.E.; Camacho R.J.; Otelea D. Drug resistance mutations for surveillance of transmitted HIV-1 drug resistance: 2009 update. PLoS One, 2009; 4:e4724.
87. Shafer, R. W.; Rhee, S. Y.; Bennett, D. E. Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies. Antivir Ther., 2008, 13 Suppl 2, 59-68.
88. Stanford HIV Drug Resistance Database. http://HIVdb.stanford.edu/ (Accessed October 30, 2010).
89. Hedt B.L.; Wadonda-Kabondo N.; Makombe S. Early warning indicators for HIV Drug resistance in Malawi. Antivir. Ther., 2008; 13 Suppl 2, 69-75.
90. Hong, S. Y.; Jonas, A.; Dumeni, E.; Badi, A.; Pereko, D.; Blom, A.; Muthiani, V. S.; Shiningavamwe, A. N.; Mukamba, J.; Andemichael, G.; Barbara, R.; Bennett, D. E.; Jordan, M. R. Population-based monitoring of HIV drug resistance in namibia with early warning indicators. J. Acquir. Immune Defic. Syndr., 2010.
91. Maphalala, G.; Okello, V.; Mndzebele, S.; Gwebu, P.; Mulima, N.; Dlamini, S.; Nhlabatsi, B.; Ginindza, T.; Ghebrenegus, Y.; Ntilivamunda, A.; Mwanyumba, F.; Ledwaba, J.; Pillay, V.; Bennett, D. E. Surveillance of transmitted HIV Drug resistance in the manzinimbabane corridor, Swaziland, in 2006. Antivir. Ther., 2008, 13 Suppl. 2, 95-100.
92. Somi, G. R.; Kibuka, T.; Diallo, K.; Tuhuma, T.; Bennett, D. E.; Yang, C.; Kagoma, C.; Lyamuya, E. F.; Swai, R. O.; Kassim, S. Surveillance of transmitted HIV Drug resistance among women attending antenatal clinics in dar es salaam, Tanzania. Antivir. Ther., 2008, 13 Suppl. 2, 77-82.
93. Aghokeng, A. F.; Vergne, L.; Mpoudi-Ngole, E.; Mbangue, M.; Deoudje, N.; Mokondji, E.; Nambei, W. S.; Peyou-Ndi, M. M.; Moka, J. J.; Delaporte, E.; Peeters, M. Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four central african countries. Antivir. Ther., 2009, 14, 401-411.
94. Pillay, V.; Ledwaba, J.; Hunt, G.; Rakgotho, M.; Singh, B.; Makubalo, L.; Bennett, D. E.; Puren, A.; Morris, L. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in gauteng province, South Africa in 2002 and 2004. Antivir. Ther., 2008, 13 Suppl. 2, 101-107.
95. Ledwaba J.; Hunt G.; Rakgotho M.; El-Khatib Z.; Singh B.; Makubalo L.; Puren A.; Morris L. HIV-1 transmitted drug resistance surveillance in three provinces in South Africa during 2002-2007. Antivir. Ther., 2009, 14 Suppl 1, A182.
96. Abegaz, W. E.; Grossman, Z.; Wolday, D.; Ram, D.; Kaplan, J.; Sibide, K.; Wuhib, T.; Ismael, S.; Nkengasong, J.; Mekonen, T.; Berhanu, H.; Messele, T.; Lulseged, S.; Maayan, S.; Mengistu, Y. Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in addis ababa, Ethiopia. Antivir. Ther., 2008, 13 Suppl 2, 89-94.
97. Kamoto, K.; Aberle-Grasse, J.; Malawi HIV drug resistance task force surveillance of transmitted HIV drug resistance with the world health organization threshold survey method in lilongwe, Malawi. Antivir. Ther., 2008, 13 Suppl 2, 83-87.
98. Ndembi, N.; Lyagoba, F.; Nanteza, B.; Kushemererwa, G.; Serwanga, J.; Katongole-Mbidde, E.; Grosskurth, H.; Kaleebu, P.; Uganda HIV drug resistance working group transmitted antiretroviral drug resistance surveillance among newly HIV type 1-diagnosed women attending an antenatal clinic in entebbe, Uganda. AIDS Res. Hum. Retroviruses, 2008, 24, 889-895.
99. Nguyen, H. T.; Duc, N. B.; Shrivastava, R.; Tran, T.H.; Nguyen, T.A.; Thang, P.H.; McNicholl, J.M.; Leelawiwat, W.; Chonwattana, W.; Sidibe, K.; Fujita, M.; Luu, C.M.; Kakkar, R.; Bennett, D.E.; Kaplan, J.; Cosimi, L.; Wolfe, M. I. HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in hanoi, Vietnam. Antivir. Ther., 2008, 13 Suppl. 2, 115-121.
100. Sirivichayakul, S.; Phanuphak, P.; Pankam, T.; O'Charoen, R.; Sutherland, D.; Ruxrungtham, K. HIV Drug resistance transmission threshold survey in Bangkok, Thailand. Antivir. Ther., 2008, 13(Suppl. 2), 109-113.
101. World Health Organization. HIV Drug Resistance Prevention, Surveillance and Monitoring in the Western Pacific Region. http://www.wpro.who.int/internet/resources.ashx/HSI/docs/HIV+Drug+Resistance+Surveillance.pdf (Accessed October 30, 2010).